Literature DB >> 23034152

Methodological quality of systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane systematic reviews in assisted reproductive technologies.

B Windsor1, I Popovich, V Jordan, M Showell, B Shea, C Farquhar.   

Abstract

STUDY QUESTION: Are there differences in the methodological quality of Cochrane systematic reviews (CRs) and non-Cochrane systematic reviews (NCRs) of assisted reproductive technologies? SUMMARY ANSWER: CRs on assisted reproduction are of higher methodological quality than similar reviews published in other journals. WHAT IS KNOWN ALREADY: The quality of systematic reviews varies. STUDY DESIGN, SIZE AND DURATION: This was a cross-sectional study of 30 CR and 30 NCR systematic reviews that were randomly selected from the eligible reviews identified from a literature search for the years 2007-2011. MATERIALS, SETTING AND METHODS: We extracted data on the reporting and methodological characteristics of the included systematic reviews. We assessed the methodological quality of the reviews using the 11-domain Measurement Tool to Assess the Methodological Quality of Systematic Reviews (AMSTAR) tool and subsequently compared CR and NCR systematic reviews. MAIN RESULTS AND THE ROLE OF CHANCE: The AMSTAR quality assessment found that CRs were superior to NCRs. For 10 of 11 AMSTAR domains, the requirements were met in >50% of CRs, but only 4 of 11 domains showed requirements being met in >50% of NCRs. The strengths of CRs are the a priori study design, comprehensive literature search, explicit lists of included and excluded studies and assessments of internal validity. Significant failings in the CRs were found in duplicate study selection and data extraction (67% meeting requirements), assessment for publication bias (53% meeting requirements) and reporting of conflicts of interest (47% meeting requirements). NCRs were more likely to contain methodological weaknesses as the majority of the domains showed <40% of reviews meeting requirements, e.g. a priori study design (17%), duplicate study selection and data extraction (17%), assessment of study quality (27%), study quality in the formulation of conclusions (23%) and reporting of conflict of interests (10%). LIMITATIONS, REASONS FOR CAUTION: The AMSTAR assessment can only judge what is reported by authors. Although two of the five authors are involved in the production of CRs, the risk of bias was reduced by not involving these authors in the assessment of the systematic review quality. WIDER IMPLICATIONS OF THE
FINDINGS: Not all systematic reviews are equal. The reader needs to consider the quality of the systematic review when they consider the results and the conclusions of a systematic review. STUDY FUNDING/COMPETING INTEREST(S): There are no conflicts with any commercial organization. Funding was provided for the students by the summer studentship programme of the Faculty of Medical and Health Sciences of the University of Auckland.

Entities:  

Mesh:

Year:  2012        PMID: 23034152     DOI: 10.1093/humrep/des342

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  13 in total

Review 1.  Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration.

Authors:  Elizabeth A Parker; Tina Roy; Christopher R D'Adamo; L Susan Wieland
Journal:  Nutrition       Date:  2017-07-06       Impact factor: 4.008

2.  Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?

Authors:  Kristina Lindsley; Tianjing Li; Elizabeth Ssemanda; Gianni Virgili; Kay Dickersin
Journal:  Ophthalmology       Date:  2016-01-22       Impact factor: 12.079

3.  Barriers to the registration and conduct of Cochrane systematic reviews of traditional East Asian medicine therapies.

Authors:  L Susan Wieland; Ruth Brassington; Geraldine Macdonald
Journal:  Eur J Integr Med       Date:  2019-11-10       Impact factor: 1.314

Review 4.  Quality of conduct and reporting in rapid reviews: an exploration of compliance with PRISMA and AMSTAR guidelines.

Authors:  Shannon E Kelly; David Moher; Tammy J Clifford
Journal:  Syst Rev       Date:  2016-05-10

Review 5.  Clinical trials registries are underused in the pregnancy and childbirth literature: a systematic review of the top 20 journals.

Authors:  Vadim V Yerokhin; Branden K Carr; Guy Sneed; Matt Vassar
Journal:  BMC Res Notes       Date:  2016-10-21

Review 6.  Identifying approaches for assessing methodological and reporting quality of systematic reviews: a descriptive study.

Authors:  Kusala Pussegoda; Lucy Turner; Chantelle Garritty; Alain Mayhew; Becky Skidmore; Adrienne Stevens; Isabelle Boutron; Rafael Sarkis-Onofre; Lise M Bjerre; Asbjørn Hróbjartsson; Douglas G Altman; David Moher
Journal:  Syst Rev       Date:  2017-06-19

7.  Meta-analysis of the clinical behavior of posterior direct resin restorations: Low polymerization shrinkage resin in comparison to methacrylate composite resin.

Authors:  Paula de Castro Kruly; Marcelo Giannini; Renata Corrêa Pascotto; Laíse Midori Tokubo; Uhana Seifert Guimarães Suga; Any de Castro Ruiz Marques; Raquel Sano Suga Terada
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

8.  Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews.

Authors:  Carole Lunny; Dawid Pieper; Pierre Thabet; Salmaan Kanji
Journal:  BMC Med Res Methodol       Date:  2021-07-07       Impact factor: 4.615

9.  Systematic review adherence to methodological or reporting quality.

Authors:  Kusala Pussegoda; Lucy Turner; Chantelle Garritty; Alain Mayhew; Becky Skidmore; Adrienne Stevens; Isabelle Boutron; Rafael Sarkis-Onofre; Lise M Bjerre; Asbjørn Hróbjartsson; Douglas G Altman; David Moher
Journal:  Syst Rev       Date:  2017-07-19

10.  A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer.

Authors:  Marius Goldkuhle; Vikram M Narayan; Aaron Weigl; Philipp Dahm; Nicole Skoetz
Journal:  BMJ Open       Date:  2018-03-25       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.